Zevra Therapeutics shareholders reject board declassification proposal at annual meeting

Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read

Key Changes

• medium

  Proposal to eliminate classified board structure failed to reach required 66.7% supermajority, receiving only 55% support. The staggered board will remain, limiting shareholders' ability to replace directors annually.

  Item 5.07 verify on EDGAR →
• low

  Douglas W. Calder and Corey Watton elected as Class II directors with terms through 2029. Calder received 76% support, Watton received 89% support.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for fiscal year 2026 with 99% approval.

  Item 5.07 verify on EDGAR →